Capital Southwest Corporation (CSWC)

Revance Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $23.75, which forecasts a 4.95% increase in the stock price over the next year. The lowest target is $22.5 and the highest is $25.

Price Target: $23.75 (+4.95%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$22.5	$23.75	$24.5	$25
Change	-0.57%	+4.95%	+8.26%	+10.47%

Analyst Ratings

The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	0	0	0	0	0	0
Buy	1	0	1	2	2	2
Hold	2	3	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Vilas Abraham UBS	UBS	Hold Maintains $21 → $23	Hold	Maintains	$21 → $23	-0.57%	Jul 16, 2025
Devin Ryan JMP Securities	JMP Securities	Hold → Buy Upgrades $25	Hold → Buy	Upgrades	$25	+10.47%	Jun 24, 2025
Robert Dodd Raymond James	Raymond James	Buy Maintains $24 → $23	Buy	Maintains	$24 → $23	+1.63%	May 16, 2025
Vilas Abraham UBS	UBS	Hold Maintains $24 → $21	Hold	Maintains	$24 → $21	-9.41%	Apr 17, 2025
Bryce Rowe B. Riley Securities	B. Riley Securities	Hold Maintains $24 → $25	Hold	Maintains	$24 → $25	+8.26%	Oct 30, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

230.15M

Increased by 12.58%

from 204.44M

Revenue Next Year

259.31M

Increased by 12.67%

from 230.15M

EPS This Year

2.38

Increased by 61.84%

from 1.47

EPS Next Year

2.35

Decreased by -1.08%

from 2.38

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027	Mar 31, 2028
Revenue	68.06M	82.22M	119.30M	178.14M	204.44M	230.15M	259.31M	-
Revenue Growth	9.71%	20.79%	45.11%	49.32%	14.77%	12.58%	12.67%	-
EPS	2.67	1.87	1.10	2.05	1.47	2.38	2.35	2.37
EPS Growth	-	-29.78%	-41.32%	86.14%	-28.32%	61.84%	-1.08%	0.72%
Forward PE	-	-	-	-	-	9.53	9.63	9.56
No. Analysts	-	-	-	-	-	10	9	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	243.8M	292.7M
Avg	230.2M	259.3M
Low	206.3M	232.1M

Revenue Growth

Revenue Growth	2026	2027
High	19.3%	27.2%
Avg	12.6%	12.7%
Low	0.9%	0.8%

EPS Forecast

EPS	2026	2027	2028
High	2.61	2.57	2.44
Avg	2.38	2.35	2.37
Low	2.10	2.11	2.27

EPS Growth

EPS Growth	2026	2027	2028
High	77.6%	8.3%	3.7%
Avg	61.8%	-1.1%	0.7%
Low	42.9%	-11.3%	-3.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.